Cargando…
Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma
Despite advances in our understanding of the biology of chromophobe renal cell carcinoma (ChRCC) and renal oncocytoma (RO), the differential diagnosis among these tumors remains one of the most problematic in renal pathology. Today, CK7 is the most recommended marker to distinguish these entities, h...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815282/ https://www.ncbi.nlm.nih.gov/pubmed/30467700 http://dx.doi.org/10.1007/s12253-018-0548-8 |
_version_ | 1783463150403715072 |
---|---|
author | Kowalewski, Adam Szylberg, Łukasz Tyloch, Janusz Antosik, Paulina Neska-Długosz, Izabela Frąckowski, Łukasz Tyloch, Dominik Purpurowicz, Piotr Grzanka, Dariusz |
author_facet | Kowalewski, Adam Szylberg, Łukasz Tyloch, Janusz Antosik, Paulina Neska-Długosz, Izabela Frąckowski, Łukasz Tyloch, Dominik Purpurowicz, Piotr Grzanka, Dariusz |
author_sort | Kowalewski, Adam |
collection | PubMed |
description | Despite advances in our understanding of the biology of chromophobe renal cell carcinoma (ChRCC) and renal oncocytoma (RO), the differential diagnosis among these tumors remains one of the most problematic in renal pathology. Today, CK7 is the most recommended marker to distinguish these entities, however it appears insufficiently accurate by itself. This study aimed to find an easily accessible IHC stain that might out-compete CK7 in this field. Expressions of CK7, cyclin D1, p16, survivin, CD138, Ki-67 and caspase 3 (CASP3) were analyzed in a total of 27 cases (20 ROs and 7 ChRCCs). Immunoreactivity was assessed based on a combined score of the extent and intensity of staining. Compared to RO, a higher percentage of the total ChRCCs stained positive for CK7 (67% vs. 22%, respectively) and CASP3 (86% vs. 25%) (P < 0.005). The differences in staining with cyclin D1, p16, survivin, CD138 and Ki-67 turned out to be statistically insignificant in differentiating ChRCC from RO. CASP3 is a promising marker in distinguishing ChRCC from RO and may represent an alternative for CK7. Cyclin D1, p16, survivin, CD138 and Ki-67 cannot be used to distinguish these neoplasms. |
format | Online Article Text |
id | pubmed-6815282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-68152822019-11-06 Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma Kowalewski, Adam Szylberg, Łukasz Tyloch, Janusz Antosik, Paulina Neska-Długosz, Izabela Frąckowski, Łukasz Tyloch, Dominik Purpurowicz, Piotr Grzanka, Dariusz Pathol Oncol Res Original Article Despite advances in our understanding of the biology of chromophobe renal cell carcinoma (ChRCC) and renal oncocytoma (RO), the differential diagnosis among these tumors remains one of the most problematic in renal pathology. Today, CK7 is the most recommended marker to distinguish these entities, however it appears insufficiently accurate by itself. This study aimed to find an easily accessible IHC stain that might out-compete CK7 in this field. Expressions of CK7, cyclin D1, p16, survivin, CD138, Ki-67 and caspase 3 (CASP3) were analyzed in a total of 27 cases (20 ROs and 7 ChRCCs). Immunoreactivity was assessed based on a combined score of the extent and intensity of staining. Compared to RO, a higher percentage of the total ChRCCs stained positive for CK7 (67% vs. 22%, respectively) and CASP3 (86% vs. 25%) (P < 0.005). The differences in staining with cyclin D1, p16, survivin, CD138 and Ki-67 turned out to be statistically insignificant in differentiating ChRCC from RO. CASP3 is a promising marker in distinguishing ChRCC from RO and may represent an alternative for CK7. Cyclin D1, p16, survivin, CD138 and Ki-67 cannot be used to distinguish these neoplasms. Springer Netherlands 2018-11-22 2019 /pmc/articles/PMC6815282/ /pubmed/30467700 http://dx.doi.org/10.1007/s12253-018-0548-8 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Kowalewski, Adam Szylberg, Łukasz Tyloch, Janusz Antosik, Paulina Neska-Długosz, Izabela Frąckowski, Łukasz Tyloch, Dominik Purpurowicz, Piotr Grzanka, Dariusz Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma |
title | Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma |
title_full | Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma |
title_fullStr | Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma |
title_full_unstemmed | Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma |
title_short | Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma |
title_sort | caspase 3 as a novel marker to distinguish chromophobe renal cell carcinoma from oncocytoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815282/ https://www.ncbi.nlm.nih.gov/pubmed/30467700 http://dx.doi.org/10.1007/s12253-018-0548-8 |
work_keys_str_mv | AT kowalewskiadam caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma AT szylbergłukasz caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma AT tylochjanusz caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma AT antosikpaulina caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma AT neskadługoszizabela caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma AT frackowskiłukasz caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma AT tylochdominik caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma AT purpurowiczpiotr caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma AT grzankadariusz caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma |